Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
JAMA Editors' Summary
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more
Author
American Medical Association
Published
Tue 09 May 2017
Episode Link
http://dx.doi.org/10.1001/jama.2016.13119
May 09, 2017 edition of the weekly JAMA Editors' Summary
Share to:
